pharmaphorum May 3, 2023
By Phil Taylor

h2o Therapeutics will soon be able to call on the marketing reach of pharma distributor AmerisourceBergen for its app for patients with Parkinson’s disease.

The Turkish digital health company received FDA approval for the Parky app last November as a prescription digital therapeutic (DTx), used to monitor symptoms such as tremors and dyskinesia in Parkinson’s patients in real-time using the Apple Watch.

That came just a few months after AmerisourceBergen launched DTx Connect, a system designed to help physicians order prescription and non-prescription DTx products and handle dispensing and fulfilment. Now h2o has joined other DTx players like Mahana Therapeutics and Videra Health by making its app available on the platform.

Parky was approved on the back of a study...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Apps, Digital Health, Technology
Medicare insurers ranked by mobile app quality
How an App Store Approach Fuels Innovation and Efficiency in Healthcare
'The generation that created the internet is now our audience': SCAN Group prepares to launch first mobile app
Apple’s Vision Pro has a problem a year into its existence: Not enough apps
Research reveals concerning links between fitness apps and disordered eating

Share This Article